[go: up one dir, main page]

MA30433B1 - Derives de pyrazolo [3,4-d] pyrimidine utilises pour traiter les troubles respiratoires - Google Patents

Derives de pyrazolo [3,4-d] pyrimidine utilises pour traiter les troubles respiratoires

Info

Publication number
MA30433B1
MA30433B1 MA31421A MA31421A MA30433B1 MA 30433 B1 MA30433 B1 MA 30433B1 MA 31421 A MA31421 A MA 31421A MA 31421 A MA31421 A MA 31421A MA 30433 B1 MA30433 B1 MA 30433B1
Authority
MA
Morocco
Prior art keywords
pyrazolo
pyrimidine derivatives
respiratory disorders
treating respiratory
disorders
Prior art date
Application number
MA31421A
Other languages
English (en)
Inventor
Ian Bruce
Judy Fox Hayler
Graham Charles Bloomfield
Lee Edwards
Brian Cox
Catherine Howsham
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36687588&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30433(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA30433B1 publication Critical patent/MA30433B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE UN COMPOSÉ DE FORMULE (I) OU UN SEL OU UN SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, DANS LAQUELLE R1-R3 ET Y SONT DÉFINIS DANS LA DESCRIPTION, ET SON UTILISATION DANS LE TRAITEMENT DE TROUBLES DANS LESQUELS LA KINASE PI3 EST IMPLIQUÉE.
MA31421A 2006-05-23 2008-11-26 Derives de pyrazolo [3,4-d] pyrimidine utilises pour traiter les troubles respiratoires MA30433B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0610242.0A GB0610242D0 (en) 2006-05-23 2006-05-23 Organic compounds

Publications (1)

Publication Number Publication Date
MA30433B1 true MA30433B1 (fr) 2009-05-04

Family

ID=36687588

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31421A MA30433B1 (fr) 2006-05-23 2008-11-26 Derives de pyrazolo [3,4-d] pyrimidine utilises pour traiter les troubles respiratoires

Country Status (24)

Country Link
US (5) US20090131457A1 (fr)
EP (1) EP2026811A1 (fr)
JP (1) JP2009537580A (fr)
KR (1) KR101106853B1 (fr)
CN (1) CN101443013A (fr)
AR (2) AR061057A1 (fr)
AU (1) AU2007253615B2 (fr)
BR (1) BRPI0712022A2 (fr)
CA (1) CA2650661A1 (fr)
CL (1) CL2007001455A1 (fr)
CR (1) CR10419A (fr)
EC (1) ECSP088902A (fr)
GB (1) GB0610242D0 (fr)
GT (1) GT200800256A (fr)
IL (1) IL195017A0 (fr)
MA (1) MA30433B1 (fr)
MX (1) MX2008014835A (fr)
NO (1) NO20084997L (fr)
PE (1) PE20080315A1 (fr)
RU (1) RU2008150619A (fr)
TN (1) TNSN08478A1 (fr)
TW (1) TW200806665A (fr)
WO (1) WO2007134828A1 (fr)
ZA (1) ZA200809097B (fr)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1831225A2 (fr) 2004-11-19 2007-09-12 The Regents of the University of California Pyrazolopyrimidines anti-inflammatoires
KR20090017498A (ko) 2006-04-04 2009-02-18 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 Ｐｉ３ 키나제 길항물질
CA2694275A1 (fr) * 2007-07-26 2009-01-29 Novartis Ag Composes organiques
EP2183232B1 (fr) 2007-08-02 2013-03-06 Amgen, Inc Modulateur de la pi3 kinase et leurs procédés d'utilisation
WO2009046448A1 (fr) 2007-10-04 2009-04-09 Intellikine, Inc. Entités chimiques et leurs utilisations thérapeutiques
CA2710194C (fr) 2007-12-19 2014-04-22 Amgen Inc. Inhibiteurs de la p13 kinase
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
WO2009088990A1 (fr) 2008-01-04 2009-07-16 Intellikine, Inc. Entités chimiques, compositions et procédés
EP2252293B1 (fr) 2008-03-14 2018-06-27 Intellikine, LLC Inhibiteurs de kinases, et procédés d utilisation associés
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
EP2111861A1 (fr) * 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions d'inhibiteurs de type IV de la phosphodiestérase
AU2009260447B2 (en) 2008-05-30 2012-03-29 Amgen Inc. Inhibitors of PI3 kinase
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
BRPI0915231A2 (pt) 2008-07-08 2018-06-12 Intellikine Inc compostos inibidores de quinase e métodos de uso
US8220787B2 (en) * 2008-09-19 2012-07-17 Panasonic Corporation Part mounting device
CA2738429C (fr) 2008-09-26 2016-10-25 Intellikine, Inc. Inhibiteurs heterocycliques de kinases
DK2358720T3 (en) 2008-10-16 2016-06-06 Univ California Heteroarylkinaseinhibitorer fused-ring
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
CA2756871A1 (fr) 2009-03-31 2010-10-07 Arqule, Inc. Composes heterocycliques substitues
EP2427195B1 (fr) 2009-05-07 2019-05-01 Intellikine, LLC Composés hétérocycliques et leurs utilisations
WO2011041634A1 (fr) * 2009-10-02 2011-04-07 Vertex Pharmaceuticals Incorporated Pyrazoles inhibiteurs de phosphatidylinositol 3-kinase
WO2011047384A2 (fr) 2009-10-16 2011-04-21 The Regents Of The University Of California Procédés d'inhibition de l'activité ire1
GB201004311D0 (en) 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
WO2011146313A1 (fr) * 2010-05-19 2011-11-24 The University Of North Carolina At Chapel Hill Composés de pyrazolopyrimidine pour le traitement du cancer
US8604032B2 (en) 2010-05-21 2013-12-10 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
EP2637669A4 (fr) 2010-11-10 2014-04-02 Infinity Pharmaceuticals Inc Composés hétérocycliques et utilisations de ceux-ci
NZ612909A (en) 2011-01-10 2015-09-25 Infinity Pharmaceuticals Inc Processes for preparing isoquinolinones and solid forms of isoquinolinones
US8362023B2 (en) 2011-01-19 2013-01-29 Hoffmann-La Roche Inc. Pyrazolo pyrimidines
TWI592411B (zh) 2011-02-23 2017-07-21 英特爾立秦有限責任公司 激酶抑制劑之組合及其用途
TWI565709B (zh) 2011-07-19 2017-01-11 英菲尼提製藥股份有限公司 雜環化合物及其用途
EP2734520B1 (fr) 2011-07-19 2016-09-14 Infinity Pharmaceuticals, Inc. Composés hétérocycliques et leurs utilisations
RU2014111823A (ru) 2011-08-29 2015-10-10 Инфинити Фармасьютикалз, Инк. Гетероциклические соединения и их применения
WO2013077921A2 (fr) 2011-09-02 2013-05-30 The Regents Of The University Of California Pyrazolo[3,4-d]pyrimidines substituées et utilisations de celles-ci
GB201115853D0 (en) 2011-09-14 2011-10-26 Proximagen Ltd New enzyme inhibitor compounds
EA201490451A1 (ru) 2011-09-14 2014-12-30 Проксимаген Лимитед Новые соединения - ингибиторы ферментов
US9273056B2 (en) 2011-10-03 2016-03-01 The University Of North Carolina At Chapel Hill Pyrrolopyrimidine compounds for the treatment of cancer
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
KR20150018789A (ko) 2012-05-22 2015-02-24 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 암의 치료를 위한 피리미딘 화합물
BR112014028881A2 (pt) 2012-05-23 2017-06-27 Hoffmann La Roche populações de células, banco de células, métodos de obtenção de uma população de células, métodos de identificação de um fator, métodos de seleção, métodos de fornecimento de terapia, populações de hepatócitos e método de obtenção de células
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
KR20150061651A (ko) 2012-09-26 2015-06-04 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Ire1의 조절
US9562047B2 (en) 2012-10-17 2017-02-07 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
CA2890105C (fr) 2012-11-01 2023-03-21 Infinity Pharmaceuticals, Inc. Traitement de cancers a l'aide de modulateurs d'isoforme de pi3 kinase
WO2014085225A1 (fr) 2012-11-27 2014-06-05 The University Of North Carolina At Chapel Hill Composés à base de pyrimidine utilisables à des fins de traitement du cancer
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9724354B2 (en) 2013-03-22 2017-08-08 Millennium Pharmaceuticals, Inc. Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase
SG10201902074UA (en) 2013-10-04 2019-04-29 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
WO2015051241A1 (fr) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Composés hétérocycliques et leurs utilisations
CN113616656B (zh) 2014-03-19 2023-02-17 无限药品股份有限公司 用于治疗PI3K-γ介导的障碍的杂环化合物
US20150291609A1 (en) 2014-04-11 2015-10-15 The University Of North Carolina At Chapel Hill Mertk-specific pyrimidine compounds
WO2015160975A2 (fr) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Polythérapies
WO2016054491A1 (fr) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Composés hétérocycliques et leurs utilisations
CZ308056B6 (cs) * 2015-07-20 2019-11-27 Ustav Experimentalni Botaniky Av Cr V V I 5-Substituované-7-[4-(substituované)benzyl]amino-3-isopropylpyrazolo[4,3-d]pyrimidiny, jejich použití jako antirevmatika, a farmaceutické přípravky
AU2016322552B2 (en) 2015-09-14 2021-03-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
US10709708B2 (en) 2016-03-17 2020-07-14 The University Of North Carolina At Chapel Hill Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
WO2017161116A1 (fr) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues de composés isoquinolinone et quinazolinone et leurs utilisations comme inhibiteurs de la kinase pi3k
LT3442535T (lt) 2016-04-15 2022-10-25 Cancer Research Technology Limited Heterocikliniai junginiai kaip ret kinazės inhibitoriai
RS62322B1 (sr) 2016-04-15 2021-10-29 Cancer Research Tech Ltd Heterociklična jedinjenja kao inhibitori ret kinaze
WO2017214269A1 (fr) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Composés hétérocycliques et leurs utilisations
WO2017223422A1 (fr) 2016-06-24 2017-12-28 Infinity Pharmaceuticals, Inc. Polythérapies
JOP20180009A1 (ar) 2017-02-06 2019-01-30 Gilead Sciences Inc مركبات مثبط فيروس hiv
GB201705971D0 (en) 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds
CN115151550B (zh) * 2019-12-23 2024-11-22 桑福德·伯纳姆·普雷比医学发现研究所 外核苷酸焦磷酸酶/磷酸二酯酶1(enpp1)调节剂及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR205429A1 (es) * 1971-04-27 1976-05-07 Ciba Geigy Ag Procedimiento para la elaboracion de nuevos derivados de 4-amino - 3-(5-nitro- 2 -furil)-1-metil - 1h - pirazol-(3,4-ol)-pirimidina
AR205234A1 (es) * 1974-05-13 1976-04-12 Lilly Co Eli Procedimiento p a r a preparar compuestos de 3-(5-nitroimidazol-2-il) pirazolo (3,4-d) pirimidina
US4044130A (en) * 1974-07-03 1977-08-23 Ciba-Geigy Corporation Compositions for the control of microorganisms
JPS5195094A (en) * 1975-01-31 1976-08-20 * ***** ****so*shi***** *o*u****** ********ne***u**** *** *** ****ne*** *************te***ku**
ES2233383T3 (es) * 1999-06-08 2005-06-16 Lorantis Limited Utilizacion terapeutica de un ihibidor de la via de señalizacion hedgehog.
NZ517758A (en) * 1999-09-17 2004-06-25 Abbott Gmbh & Co Pyrazolopyrimidines useful as therapeutic agents
KR100785363B1 (ko) * 2000-04-25 2007-12-18 이코스 코포레이션 인간 포스파티딜-이노시톨 3-키나제 델타의 억제제
EP1432714B1 (fr) * 2001-10-02 2008-08-06 Smithkline Beecham Corporation Composes chimiques
AU2003225933A1 (en) * 2002-03-22 2003-10-13 Cellular Genomics, Inc. AN IMPROVED FORMULATION OF CERTAIN PYRAZOLO(3,4-d) PYRIMIDINES AS KINASE MODULATORS
US7429596B2 (en) * 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
CA2553724A1 (fr) * 2004-02-03 2005-08-18 Abbott Laboratories Utilisation d'aminobenzoxazoles comme agents therapeutiques
EP1831225A2 (fr) * 2004-11-19 2007-09-12 The Regents of the University of California Pyrazolopyrimidines anti-inflammatoires
JP2009531443A (ja) * 2006-03-29 2009-09-03 フォールドアールエックス ファーマシューティカルズ インコーポレーティッド α−シヌクレイン毒性の抑制

Also Published As

Publication number Publication date
CL2007001455A1 (es) 2008-05-16
KR101106853B1 (ko) 2012-01-19
NO20084997L (no) 2008-12-22
RU2008150619A (ru) 2010-06-27
AR061057A1 (es) 2008-07-30
AR110051A2 (es) 2019-02-20
ECSP088902A (es) 2008-12-30
US8901134B2 (en) 2014-12-02
TNSN08478A1 (en) 2010-04-14
TW200806665A (en) 2008-02-01
MX2008014835A (es) 2008-12-01
CA2650661A1 (fr) 2007-11-29
US20090131457A1 (en) 2009-05-21
JP2009537580A (ja) 2009-10-29
GT200800256A (es) 2009-05-28
IL195017A0 (en) 2009-08-03
KR20090008392A (ko) 2009-01-21
US20140235632A1 (en) 2014-08-21
AU2007253615B2 (en) 2011-06-23
ZA200809097B (en) 2009-11-25
PE20080315A1 (es) 2008-06-11
US20180125849A1 (en) 2018-05-10
US20160303132A1 (en) 2016-10-20
GB0610242D0 (en) 2006-07-05
WO2007134828A1 (fr) 2007-11-29
US20140051698A1 (en) 2014-02-20
AU2007253615A1 (en) 2007-11-29
EP2026811A1 (fr) 2009-02-25
CN101443013A (zh) 2009-05-27
CR10419A (es) 2011-07-19
BRPI0712022A2 (pt) 2011-12-27

Similar Documents

Publication Publication Date Title
MA30433B1 (fr) Derives de pyrazolo [3,4-d] pyrimidine utilises pour traiter les troubles respiratoires
SA521421205B1 (ar) مشتقات 6-(4-أمينو-3-أوكسا-8-ازاسبيرو[4.5]ديكان-8-يل)-3-(2.3-داي كلورو فينيل)-2-ميثيل بيريميدين-4(3h)-اون والمركبات ذات الصلة مثل مثبطات ptpn11 (shp2) لعلاج السرطان
DE60316013D1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
HRP20090281T1 (hr) 1,2,3,4-tetrasubstituirani indol za liječenje respiratornih bolesti
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
MX2008013836A (es) Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
EA200900152A1 (ru) Ингибиторы пирролотриазинкиназы
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
GB0112348D0 (en) Compounds
MY141220A (en) Pyrazole derivatives as inhibitors of receptor tyrosine kinases
TW200621762A (en) Novel compounds
ATE473980T1 (de) Triazolopyridazine als proteinkinase-inhibitoren
NO20072795L (no) Pyrazol [1,5-a]pyrimidiner som er nyttige som inhibitorer av proteinkinaser
AU2003297160A1 (en) Benzisoxazole derivatives useful as inhibitors of protein kinases
LU92155I2 (fr) Crizotinib, éventuellement sous la forme d'un sel,hydrate ou solvate pharmeceutiquement acceptable
DE602004022668D1 (de) 5-gliedrige heterocyclische p-38 inhibitoren
MXPA05011166A (es) Antagonistas del receptor del peptido relacionado con el gen de la calcitonina.
EA200900733A1 (ru) ЗАМЕЩЁННЫЕ ПРОИЗВОДНЫЕ 2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИНА, ПОЛЕЗНЫЕ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ НАРУШЕНИЙ И БОЛЕЗНЕЙ, СВЯЗАННЫХ С АНГИОГЕНЕЗОМ
NO20075169L (no) Nye imidazo (1,5-A)pyndindenvater, fremgangsmate for fremstilling og farmasoytiske sammensetninger som inneholder samme.
MA58993A1 (fr) Antagoniste du récepteur crf1 pour le traitement de l'hyperplasie surrénale congénitale
WO2008079873A3 (fr) Utilisation de composés thiazolyle comme inhibiteurs de kinases
TN2009000329A1 (fr) DERIVES DE 2-AMINO-5,7-DIHYDRO-6H-PYRROLO[3,4-d]-PYRIMIDINE SERVANT D'INHBITEURS DE HSP-90 POUR LE TRAITEMENT DU CANCER
NO20091254L (no) Terapeutiske sammensetninger
NO20070837L (no) Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer.
MX2009011059A (es) Aminopirimidinas utiles como inhibidores de cinasas.